Rejuvenate Bio develops AAV gene therapies aimed at the underlying biology of aging rather than the symptoms of individual age-related diseases. The company originated from George Church's lab at Harvard and works on cardiac, metabolic and renal indications. It pursues a dual-species strategy, developing therapies for companion animals — dogs with heart disease, osteoarthritis and cancer — alongside a human program. Revenue, safety data and partner funding from the animal health path are intended to carry the platform into human medicine.